{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"5.3","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Estimated using the product-limit method of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nbelinostat: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Belinostat)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}